I don't know and haven't looked enough - this is clear as day to me that Pfizer do not care about the Dx stuff but they know that exclusive licencing isnt enough because they can see how shocking current management are at getting it to work.
I think consequently, Pfizer will go don the Dx line, but way more commercially astute and better update - once they've made the covid screen work for their business needs. I do not think they will go down exclusive licencing route as they will want full control of the actual tech etc.
Medgate is currently worth nothing and I will personally apologise if there is significant revenue from this in the upcoming quarterly. The fact that the company won't even provide rough numbers around the number of assessments or coughs that have been done commercially is astounding. Rolling nothing out to Germany is still nothing.
- Forums
- ASX - By Stock
- RAP
- Top-up fundraiser
Top-up fundraiser, page-105
Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #
-
- There are more pages in this discussion • 342 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)